Physician profile
Stephen L Tilley
NPI 1437210465
$1,246.51
in general payments reported to CMS, 2019-2025
9 companies · $424 in 2025
The $424 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $473 · 2022: $108 · 2023: $89.68 · 2024: $152 · 2025: $424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $666.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $665.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $860.80 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Viatris Specialty LLC | $139.18 | 2025 | Yupelri |
| Mylan Specialty L.P. | $83.43 | 2023-2024 | Yupelri |
| Mallinckrodt Hospital Products INC. | $74.75 | 2022 | |
| Astrazeneca Uk Limited | $32.63 | 2023 | Tezspire |
| Astrazeneca Pharmaceuticals Lp | $21.52 | 2025 | |
| Genzyme Corporation | $21.50 | 2024 | |
| Merck Sharp & Dohme LLC | $12.70 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Tilley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.